
Opinion|Videos|March 28, 2025
Balancing Approved Therapies and Patient Preference in Parkinson Disease
Author(s)Daniel E. Kremens, MD, JD
An expert discusses the importance of collaborating with patients, emphasizing the value of leading with data when educating them on the efficacy of treatments, and highlights the role of providers in supporting patients as they discover the medications and supplements that work best for them, while advocating for and protecting patients to ensure they can seek the best quality of life.
Advertisement
Episodes in this series

Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 MG0020 Trial Highlights Success of Self-Administered Rozanolixizumab for Generalized Myasthenia Gravis
2
Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials
3
Open-Label Extension Highlights Continued Therapeutic Benefit of Nipocalimab in Patients Transitioning From Placebo
4
Efgartigimod Treatment for CIDP Leads to Increased Spending, Study Shows
5








































